Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jun 29, 2024
Discovery & Translation

Science Spotlight: Microglial transplantation for ALSP, AlaMab’s osteosarcoma mAb and more

BioCentury’s roundup of translational innovations
BioCentury | May 6, 2019
Distillery Therapeutics

The GJA1 inhibitor clofazimine to treat glioblastoma

BioCentury | Feb 22, 2018
Targets & Mechanisms

Molecular mentality

How studying transcription in the brain could advance the biology of psychiatry
BioCentury | Oct 24, 2017
Distillery Techniques

Disease models

BioCentury | Sep 28, 2017
Preclinical News

Researchers report first Haplobank data

BioCentury | Aug 8, 2016
Company News

FirstString Research, Relief Therapeutics deal

BioCentury | Jun 16, 2016
Translation in Brief

Dysfunction junction

Shutting down a paracrine loop that promotes brain metastases
Items per page:
1 - 10 of 17